BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 205971)

  • 1. Platelet aggregation and cyclic nucleotide phosphodiesterase activity in arteriosclerotic patients.
    Yamazaki H; Motomiya T; Mashimo N; Asano T; Hidaka H
    Thromb Haemost; 1978 Feb; 39(1):158-66. PubMed ID: 205971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung.
    Fertel R; Weiss B
    Mol Pharmacol; 1976 Jul; 12(4):678-87. PubMed ID: 183099
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclic nucleotide phosphodiesterase activities of the human liver: comparison between control and Reye's syndrome samples.
    Kang ES
    Pediatr Res; 1978 Jul; 12(7):761-6. PubMed ID: 211480
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
    Hagiwara M; Endo T; Kanayama T; Hidaka H
    J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
    Zhou L; Thompson WJ; Potter DE
    Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple forms of cyclic nucleotide phosphodiesterases: anomalies or biologic regulators?
    Strada SJ; Thompson WJ
    Adv Cyclic Nucleotide Res; 1978; 9():265-83. PubMed ID: 208379
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cyclic nucleotide metabolism in the blood platelets and its relationship to the vascular wall].
    Yamazaki H
    Rinsho Byori; 1979; Suppl 40():40-6. PubMed ID: 233106
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclic nucleotides and platelet aggregation. Effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymes.
    Barber AJ
    Biochim Biophys Acta; 1976 Sep; 444(2):579-95. PubMed ID: 9149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
    Netherton SJ; Maurice DH
    Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
    Matsuoka I; Suzuki T
    J Cyclic Nucleotide Protein Phosphor Res; 1983; 9(4-5):341-53. PubMed ID: 6147364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerosis patients and its prevention.
    Sano T; Motomiya T; Yamazaki H; Shimamoto T
    Thromb Haemost; 1977 Apr; 37(2):329-38. PubMed ID: 195363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic nucleotide phosphodiesterase activity in normal mice and mice with retinal degeneration.
    Robb RM
    Invest Ophthalmol Vis Sci; 1979 Oct; 18(10):1097-100. PubMed ID: 225287
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
    Manns JM; Brenna KJ; Colman RW; Sheth SB
    Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic GMP binding and phosphodiesterase: implication for platelet function.
    Hamet P; Coquil JF; Bousseau-Lafortune S; Franks DJ; Tremblay J
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():119-36. PubMed ID: 6202123
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
    Simpson AW; Reeves ML; Rink TJ
    Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
    Maurice DH
    Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of mitomycin C on platelet aggregation and adenosine 3',5'-monophosphate metabolism.
    Hashimoto S; Shibata S; Kobayashi B
    Thromb Haemost; 1978 Feb; 39(1):177-85. PubMed ID: 205972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of cyclic nucleotide phosphodiesterase activity within the bovine photoreceptor cell.
    Pannbacker RG; Lovett K
    Invest Ophthalmol Vis Sci; 1977 Feb; 16(2):166-8. PubMed ID: 188779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.